Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss
Status
Conditions
Treatments
Details and patient eligibility
About
For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate. In the investigators study, patients were divided into two groups. In Group A, patients continued entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a monotherapy for 48 weeks, then followed up 24 weeks.
Full description
For HBeAg positive hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate. In our study, patients without HBeAg loss to 48 weeks entecavir treatment were divided into two groups. In Group A, patients continued entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a monotherapy for 48 weeks, then followed up 24 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age between 18 and 50 years old
- HBsAg(+) and HBeAg(+) for over 6 months before entecavir treatment
- Treated by entacavir for 48 weeks with HBeAg seroconversion
Exclusion criteria
- Pregnant women
- Decompensated liver disease
- Combination infection of HCV, HAV, or HEV
- Combination infection of HIV
- Any contraindication of interferon α
Trial design
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal